Podcasts about biobanking

Biobanking of human biospecimens has a long history. In the last two decades, several best practices have been developed, resulting in better-quality specimens. Jim Vaught, PhD, Editor Emeritus of the Biopreservation and Biobanking journal, joins the podcast to talk about the new era we are entering where new markets and technologies will result in new approaches to collecting, processing, and storing samples. Learn more about the CAP's Biorepository Accreditation Program: https://www.cap.org/laboratory-improvement/accreditation/biorepository-accreditation-program

Biobanking, Exosomes, Cryopreservation, Harvesting Stem Cells  - Join us as we explore the future of regenerative medicine with CEO and founder of Acorn Biolabs Dr. Drew Taylor and Beauty Journalist, Editorial Director at Beautytap and Contributor to The Hollywood Reporter, Elycia Rubin! Drew explains the process of how to safely harvest stem cells, invest in your own biologic health insurance policy, and dives into the "hocus pocus" that surrounds biohacking. Stay tuned to learn how you can maintain the health of your cells!

Marcie Finney is the Executive Director of the Cleveland Cord Blood Center ( https://clevelandcordblood.org/about-us/leadership/ ) where her responsibilities include strategic planning, finance, administration and quality product development. With an extensive background in the field of cord blood, she spent over 10 years at Case Western Reserve University where she participated in all aspects of cord blood research and she is active in the cellular therapy community, sharing knowledge and experiences in cord blood banking research and cellular therapy throughout the U.S. and globally. The Cleveland Cord Blood Center (CCBC), a not-for-profit 501(c)(3), is an independent public cord blood bank serving as a leader in the collection, processing, storage and distribution of quality cord blood stem cell units for transplantation in patients with life threatening disorders such as leukemia, lymphoma and immune system disorders. The Center is one of only eight FDA-approved cord blood Centers in the U.S. Prior to her current role, Marcie served as the organization's Director of Hospital Relations where she headed the education and training of collection coordinators and medical staff at hospital collection sites. She received a Master of Science in Chemistry and an MBA from Case Western Reserve University, and a Bachelor of Science in Chemistry from Slippery Rock University. Marcie also serves on the Board of Directors for the Cord Blood Association, one of the industry's foremost organizations. She is a member of the Advisory Board for Gamida, a cell therapy company that is pioneering new standards of care for patients with blood cancers and other blood diseases. She also serves on the Board of Directors for the Goodwill Industries of Greater Cleveland and East Central Ohio. Dr. Frances Verter, Ph.D., is Founder & Director of Parent's Guide to Cord Blood ( https://parentsguidecordblood.org/en/staff ), an organization she started in 1998 in memory of her daughter Shai, who when unexpectedly diagnosed with cancer, led her to become a patient advocate in order to take better care of her child. Dr. Verter started her career as a research scientist, earning a BS in physics from Brooklyn College and a Ph.D. in astrophysics from Princeton University, and she found that her training as a scientist enabled her to review medical research on Shai's diagnosis and seek out treatment from the best doctors and the best hospitals. After Shai passed away, Dr. Verter formed the Parent's Guide to Cord Blood organization and in 2006 she made a career out the project. Since then, she has thrown herself even deeper into following everything about cord blood, from education for expectant parents to the use of cord blood in clinical trials. She regularly attends conferences, gives talks, and publishes articles and is LinkedIn to professionals around the world. Dr. Verter also launched CellTrials.org as a subsidiary of the Foundation in 2017 which aims to provide the world's most complete and most accurate data on clinical trials of advanced cell therapies. Support the show

In this excerpt, Dr. Stanley Rockson chats about biorepositories and registries for lymphatic disorders.Mentioned in this episode:A Heart to Heart Collaborative Community EventJoin our sixth annual lipedema virtual Event on March 31, April 1 & 2, 2023.Join our Event!

Today, I'm joined by two fabulous guests: Marielle Gross, Assistant Professor of Obstetrics, Gynecology, and Reproductive Sciences at the University of Pittsburgh, and renaissance man, Brian Frye, the Spears-Gilbert Professor of Law at the University of Kentucky.  Marielle provides clinical care at UPMC Altoona and her research focuses on the application of technology and elimination of bias as a means of promoting evidence-basis, equity and efficiency in women's healthcare. Today, we're discussing heny, Inc., a start up that Marielle founded that utilizes NFTs to allow breast cancer patients to remain connected to their biopsy results. When patients participate in research studies, their names and identifying features are taken off of their samples – in other words, they are deidentified. What this means is that if researchers find medically relevant information, they can't pass that on to the patient. Nor can patients share in any of the profits that research on their tissue might generate. As we discuss in this episode, Marielle was inspired by the infamous Henrietta Lacks case to create a non-fungible NFT-like token that allows breast cancer patients to track and learn about research on their donated tumor and tissues.  That's where Brian Frye comes in: he teaches courses on patent and intellectural property law, and has published widely about NFTs. Many of his articles are linked in the show notes. Brian is also a filmmaker. He produced the documentary Our Nixon (2013), which was broadcast by CNN and opened theatrically nationwide. His short films and videos have shown in the 2002 Whitney Biennial, the New York Film Festival, and the San Francisco International Film Festival, among other venues, and are in the permanent collection of the Whitney Museum of American Art. If you don't get enough of Brian in this episode, then make sure to listen to my earlier bonus episode: The Plagiarism Taboo with Brian Frye.  Further reading and listening: Marielle S Gross, MD; Amelia J Hood, MA; Robert C Miller Jr, BA, Nonfungible Tokens as a Blockchain Solution to Ethical Challenges for the Secondary Use of Biospecimens: Viewpoint, JMIR Bioinform Biotech 2021;2(1):e29905) doi: 10.2196/29905; https://bioinform.jmir.org/2021/1/e29905 This Pitt professor's startup applies NFTs to bioethics, Technical.ly, Sept. 13, 2022; https://technical.ly/startups/heny-nfts-bioethics-marielle-gross/ The Plagiarism Taboo with Brian Frye, https://www.buzzsprout.com/1227113/episodes/11050801 Frye, Brian L., NFTs & the Death of Art (April 19, 2021). Available at SSRN: https://ssrn.com/abstract=3829399 or http://dx.doi.org/10.2139/ssrn.3829399 Frye, Brian L., How to Sell NFTs Without Really Trying (September 25, 2021). 13 Harvard Journal of Sports and Entertainment Law 113 (2022), Available at SSRN: https://ssrn.com/abstract=3930430 Frye, Brian L., After Copyright: Pwning NFTs in a Clout Economy (November 25, 2021). 45 Colum. J.L.& Arts 341 (2022), Available at SSRN: https://ssrn.com/abstract=3971240 or http://dx.doi.org/10.2139/ssrn.3971240 Frye, Brian L., The Art of the Token (March 16, 2022). Stanford Journal of Blockchain Law & Policy, Available at SSRN: https://ssrn.com/abstract=4059574 

It's our first episode of 2023, featuring the final episode in our occasional series on Precision Medicine at Nemours. Our topic is predictive analytics for the purpose of research. Collecting it, preparing it, analyzing it, and protecting it are the realm of the Nemours Biomedical Research Informatics Center (BRIC). BRIC provides consultation, training, and computational resources to biomedical research investigators across the enterprise and beyond. Our guests are BRIC Director Dr. Timothy Bunnell, and Daniel Eckrich, BRIC's Supervisor for Research Applications. Carol Vassar, producer Listen to other episodes in the Precision Medicine series: Episode 153: What is Precision Medicine (July 25, 2022) Episode 160: Changing Medicine through Pharmacogenomics Research (Sept. 12, 2022) Episode 161: Pharmacogenomics in Practice (Sept. 19, 2022) Episode 168: Biobanking at Nemours (Nov. 7, 2022) Episode 171: Genetic Medicine and Genetic Counseling for Kids (Nov. 28, 2022)  

According to a Transparency Market Research (TMR) research report, the global biobanking market is expected to reach US$ 87.4 Bn by the end of 2031. This suggests that the market is likely to expand at a CAGR of 5.9% during the forecast period, 2022 to 2031.The business intelligence study on the market is prepared by employing industry-validated primary and secondary methods. The study uses these to collect data, analyze them, and garner relevant and useful insights on several aspects of the market dynamics.Get Sample Copy of the Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1568The research report by TMR provides thorough analysis of key facets impacting on the growth trajectory of the biobanking industry. Hence, this report covers study on different factors such as the growth drivers, expansion avenues, growth restraints, and challenges experienced by the market players.Biobanking Market and Value Chain Analysis:The study on the market presents a critical assessment of the marketing environment including suppliers, marketing intermediaries, competitors, publics, and customers. The report offers a detailed evaluation into how these have evolved in response to the natural and technical environments.Some of the key aspects covered by the analysts in the study are:What key consumer attitudes and behaviors will influence demand in the biobanking market?What are some of the key customer value propositions in the market?What factors are driving uptick in credit demand in various industries related to the biobanking market?Which are key internal considerations affecting pricing decision for the recently launched products?How revenues in the key product segments have been impacted by supply chain and value delivery network?In which segment will research spending beat expectations by the end of the forecast period?Biobanking Market Competitive Strategies:The report on the market presents a critical assessment of frameworks for branding decisions, market fit growth strategies, and strategies for leaders and pioneers. The study analyzes distribution channel strategies, product portfolio, strategic business units of top players, and goal attacking, and market expansion strategies.Make Inquiry before Buying – https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=1568Some of the key questions scrutinized in the study are:Player 1Player 2Player 3Some of the key aspects analyzed in the study on the biobanking market are:What are some of the promotional techniques of key firms in the biobanking market?What product mix strategies leading players have adopted in recent years?How are key firms strategically entering new developed and fast-growing economies?Which key players have forged partnerships to grow their market shares during the forecast period?Which is the intensity of competition and how will fragmentation and consolidation work?How have monetary and financial policies shaped the entry barriers in the market?Biobanking Market Regional Developments: Assessment of Growth Dynamics in Key GeographiesSome of the broad aspects that the study scrutinizes areWhat are some of the financial and economic environment in geographies that underpinned growth of emerging markets?Which regions are expected to lose their sheen due to economic and political impediments?How

Today my guests are Leif Honda and Jon Wetzel from Trimetis Life Sciences  What we discuss with Jon and Leif: Their educational backgrounds and entrepreneurial inspirations How they got started in biobanking and how they came to work together Their roles at Trimetis Life Sciences Trimetis Computer Assisted Pathology (TCAP) and how this system was developed How TCAP utilizes AI Trimetis ARCH system and how it can improve biobanking efficiency What the future holds for Trimetis  Links for this episode: Health Podcast Network  LabVine Learning Bridging The Gap Between Pathology And Computer Science The ConfLab from LabVine Dress A Med scrubs   Trimetis Life Sciences on Twitter Trimetis Life Sciences website Simplifying Complex Medical Sample Procurement for Tissue & Cancer Revolutionizing Tissue-Based Research Through Pathology and Artificial Intelligence With Jon Wetzel and Leif Honda   People of Pathology Podcast: Website Twitter

Since 2018, Nasa's InSight Mars lander has been sitting on the surface listening to the seismic rumbles of the red planet's deep interior. But this week, plans were announced to finally phase down its activity, as martian dust obscures too much of its solar panels to power it through the forthcoming winter. Jon Amos tells Vic Gill of some of its many successes, and quite why it didn't fly with a duster on board. 50 years of observations across Australia's northern tropical forests suggest yet more bad news for the climate. Trees' mortality has, it seems, doubled since the 1980s. As Oxford University's David Bauman tells Vic, it seems to be linked to a drying of the air as temperatures rise, and if the trend is also true across the world's other moist tropical forests, they could rapidly slip from being carbon sinks, to carbon sources. Conservationists say we're losing animal species faster today than at any point in the last 10 million years of Earth's history. And one approach aims to save as many of those lost animals as possible – after they've died. Biobanking – saving frozen tissue from dead animals for future cloning or other reproductive technologies could buy us time to prevent extinction - or even reverse it. Vic visits Nature's Safe, where technology used in pedigree breeding is being deployed to preserve the cells and tissue of endangered species when individuals die or are euthanised, for possible research in the future, or even cloning. Meanwhile, 2.5 miles off the coast of Jersey, archaeologists are holing up in a medieval fortress waiting for the few lowest tides of the year to give them access to the Violet Bank - an area of reef thought once to have been home to Neanderthal populations, but which now is for most of the year submerged by the sea. Marnie Chesterton has been talking to UCL's Matt Pope between the ebbs and flows. Presented by Victoria Gill Reporters: Marnie Chesterton and Jonathan Amos Produced by Alex Mansfield

With another throwback to our original Biofriendly Podcast show style, we kick off this week's episode with a little Phil Collins karaoke, discuss something called BioChar, and explore how scientists are trying to save koalas and more! 

Víctor Angel is a bio-engineer and designer working at the intersection of human and planetary health. He currently serves as Founder of the Entheogen Genome Project, an open-science initiative to preserve all entheogenic flora, fauna and fungi.The Entheogen Genome Project is an international endeavor to build an open-access, genomic database of all known entheogenic flora, fauna and fungi by the year 2025. The project emerges from a variety of perspectives, all of which converge on the importance of preserving diversity, both cultural and biological, and the shared vision of an open-science platform for entheogenic research and conservation. https://www.entheome.org/https://www.entheome.org/sponsor

Dr, Christian Tiambo is a Cameroonian Scientist. Livestock Genetics/Genomics: Precision Breeding and Reproductive Technologies, Biobanking management, Access & Benefits Sharing Officer CTLGH/ILRI based in Kenya.The Vulnerable Scientist is a Kenyan-based podcast that focuses on scientists' stories about their daily lives, work, and how they got to where they are. I am your host Sarah Nyakeri, a scientist, informal science communicator and a hiker. I am a multidisciplinary individual that does digital marketing and website design during my free time.The main questions asked that scientists are expected to answer vulnerable are: How are you, Introduce yourself, how did you become a scientist, What are the highs and lows you have experienced in your science career, tell the listeners about your hobbies, what question would you like to answer that has not been asked and how do you feel after having this conversation.Why did I start this podcast? You might ask. When doing my MSc project, my experiments started to fail at a certain period and it was very frustrating. I thought, If I finally get a new vaccine target for CBPP in cows, it would be all smiles but no one will ever know what I went through. I also wondered how many scientists were going through the same rough patch but did not openly talk about it?One day when I had just had a rough day, I talked into a mic about my day and I felt better. That was the first episode. At first, I thought it would just be journalling but after some fellow scientists heard it, they wanted to be Vulnerable too. Since then I have brought scientists from different fields to tell their stories of the highs and lows they have experienced with honesty and authenticity being the lead of our informal and long conversations.I enjoy asking questions since I am a naturally curious person. Feedback from the audience, including scientists and non-scientists, is the main motivation I message scientists or accept their request to be on the podcast, schedule an interview, edit audio, design the artwork, post it, and share it on social media platforms. It is a full-time job that requires me to spend from my pocket with no monetary returns, but I enjoy it.If you want to be Vulnerable on the show, send me an audio message either on speak pipe (https://www.speakpipe.com/VulnerableScientistVoicemail ) or anchor (https://anchor.fm/thevulnerablescientist/message). Feel free to reach out too if you want to talk about a certain topic in the science career space or anything as a scientist that might have nothing to with science but affects scientists. The podcast is on social media @TVscientistPod and Website; TheVulnerablescientist.com. You can support the show (https://www.patreon.com/thevulnerablescientist) on Patreon or Paypal sarahnyanchera(at)gmail or Mpesa at (254)0718896962 under Sarah Nyakeri. Hosted on Acast. See acast.com/privacy for more information.

Dr, Christian Tiambo decides to become vulnerable on the show and tells more about the struggles he had and the triumphs of his journey in science.Scientist. Livestock Genetics/Genomics: Precision Breeding and Reproductive Technologies, Biobanking management, Access & Benefits Sharing Officer CTLGH/ILRIThe Vulnerable Scientist is a Kenyan-based podcast that focuses on scientists' stories about their daily lives, work, and how they got to where they are. I am your host Sarah Nyakeri, a scientist, informal science communicator and a hiker. I am a multidisciplinary individual that does digital marketing and website design during my free time.The main questions asked that scientists are expected to answer vulnerable are: How are you, Introduce yourself, how did you become a scientist, What are the highs and lows you have experienced in your science career, tell the listeners about your hobbies, what question would you like to answer that has not been asked and how do you feel after having this conversation.Why did I start this podcast? You might ask. When doing my MSc project, my experiments started to fail at a certain period and it was very frustrating. I thought, If I finally get a new vaccine target for CBPP in cows, it would be all smiles but no one will ever know what I went through. I also wondered how many scientists were going through the same rough patch but did not openly talk about it?One day when I had just had a rough day, I talked into a mic about my day and I felt better. That was the first episode. At first, I thought it would just be journalling but after some fellow scientists heard it, they wanted to be Vulnerable too. Since then I have brought scientists from different fields to tell their stories of the highs and lows they have experienced with honesty and authenticity being the lead of our informal and long conversations.I enjoy asking questions since I am a naturally curious person. Feedback from the audience, including scientists and non-scientists, is the main motivation I message scientists or accept their request to be on the podcast, schedule an interview, edit audio, design the artwork, post it, and share it on social media platforms. It is a full-time job that requires me to spend from my pocket with no monetary returns, but I enjoy it.If you want to be Vulnerable on the show, send me an audio message either on speak pipe (https://www.speakpipe.com/VulnerableScientistVoicemail ) or anchor (https://anchor.fm/thevulnerablescientist/message). Feel free to reach out too if you want to talk about a certain topic in the science career space or anything as a scientist that might have nothing to with science but affects scientists. The podcast is on social media @TVscientistPod and Website; TheVulnerablescientist.com. You can support the show (https://www.patreon.com/thevulnerablescientist) on Patreon or Paypal sarahnyanchera(at)gmail or Mpesa at (254)0718896962 under Sarah Nyakeri. Hosted on Acast. See acast.com/privacy for more information.

Dr, Christian Tiambo explains in detail how he was able to fund his post-graduate education while running a farming business.Scientist. Livestock Genetics/Genomics: Precision Breeding and Reproductive Technologies, Biobanking management, Access & Benefits Sharing Officer CTLGH/ILRIThe Vulnerable Scientist is a Kenyan-based podcast that focuses on scientists' stories about their daily lives, work, and how they got to where they are. I am your host Sarah Nyakeri, a scientist, informal science communicator and a hiker. I am a multidisciplinary individual that does digital marketing and website design during my free time.The main questions asked that scientists are expected to answer vulnerable are: How are you, Introduce yourself, how did you become a scientist, What are the highs and lows you have experienced in your science career, tell the listeners about your hobbies, what question would you like to answer that has not been asked and how do you feel after having this conversation.Why did I start this podcast? You might ask. When doing my MSc project, my experiments started to fail at a certain period and it was very frustrating. I thought, If I finally get a new vaccine target for CBPP in cows, it would be all smiles but no one will ever know what I went through. I also wondered how many scientists were going through the same rough patch but did not openly talk about it?One day when I had just had a rough day, I talked into a mic about my day and I felt better. That was the first episode. At first, I thought it would just be journalling but after some fellow scientists heard it, they wanted to be Vulnerable too. Since then I have brought scientists from different fields to tell their stories of the highs and lows they have experienced with honesty and authenticity being the lead of our informal and long conversations.I enjoy asking questions since I am a naturally curious person. Feedback from the audience, including scientists and non-scientists, is the main motivation I message scientists or accept their request to be on the podcast, schedule an interview, edit audio, design the artwork, post it, and share it on social media platforms. It is a full-time job that requires me to spend from my pocket with no monetary returns, but I enjoy it.If you want to be Vulnerable on the show, send me an audio message either on speak pipe (https://www.speakpipe.com/VulnerableScientistVoicemail ) or anchor (https://anchor.fm/thevulnerablescientist/message). Feel free to reach out too if you want to talk about a certain topic in the science career space or anything as a scientist that might have nothing to with science but affects scientists. The podcast is on social media @TVscientistPod and Website; TheVulnerablescientist.com. You can support the show (https://www.patreon.com/thevulnerablescientist) on Patreon or Paypal sarahnyanchera(at)gmail or Mpesa at (254)0718896962 under Sarah Nyakeri. Hosted on Acast. See acast.com/privacy for more information.

Dr Christian talks about his journey into becoming a scientist starting from Cameroon and how he ended up establishing a career in Kenya.He is a Scientist, Livestock Genetics/Genomics - Precision Breeding and Reproductive Technologies, Biobanking management, Access & Benefits Sharing Officer- at CTLGH/ILRIThe Vulnerable Scientist is a Kenyan-based podcast that focuses on scientists' stories about their daily lives, work, and how they got to where they are. I am your host Sarah Nyakeri, a scientist, informal science communicator and a hiker. I am a multidisciplinary individual that does digital marketing and website design during my free time.The main questions asked that scientists are expected to answer vulnerable are: How are you, Introduce yourself, how did you become a scientist, What are the highs and lows you have experienced in your science career, tell the listeners about your hobbies, what question would you like to answer that has not been asked and how do you feel after having this conversation.Why did I start this podcast? You might ask. When doing my MSc project, my experiments started to fail at a certain period and it was very frustrating. I thought, If I finally get a new vaccine target for CBPP in cows, it would be all smiles but no one will ever know what I went through. I also wondered how many scientists were going through the same rough patch but did not openly talk about it?One day when I had just had a rough day, I talked into a mic about my day and I felt better. That was the first episode. At first, I thought it would just be journalling but after some fellow scientists heard it, they wanted to be Vulnerable too. Since then I have brought scientists from different fields to tell their stories of the highs and lows they have experienced with honesty and authenticity being the lead of our informal and long conversations.I enjoy asking questions since I am a naturally curious person. Feedback from the audience, including scientists and non-scientists, is the main motivation I message scientists or accept their request to be on the podcast, schedule an interview, edit audio, design the artwork, post it, and share it on social media platforms. It is a full-time job that requires me to spend from my pocket with no monetary returns, but I enjoy it.If you want to be Vulnerable on the show, send me an audio message either on speak pipe (https://www.speakpipe.com/VulnerableScientistVoicemail ) or anchor (https://anchor.fm/thevulnerablescientist/message). Feel free to reach out too if you want to talk about a certain topic in the science career space or anything as a scientist that might have nothing to with science but affects scientists. The podcast is on social media @TVscientistPod and Website; TheVulnerablescientist.com. You can support the show (https://www.patreon.com/thevulnerablescientist) on Patreon or Paypal sarahnyanchera(at)gmail or Mpesa at (254)0718896962 under Sarah Nyakeri. Hosted on Acast. See acast.com/privacy for more information.

El Dr. Pedro Murúa del Instituto de Acuicultura de la Universidad Austral de Chile está encabezando un proyecto para determinar las pestes que están afectando al pelillo (BASILISK: Characterization and bioBAnking of economically-relevant pestS and pathogens of pelillo (Agarophyton chilensis), for biosecurIty riSK management tool development) y que es de gran interés para las zona de Maullín y Pudeto. Esta investigación se adjudicó uno de los 15 fondos de la Safe Seaweed Coalition y busca dar respuesta a los problemas (pestes de distinta naturaleza) que está enfrentando el pelillo (A. chilensis) que es la única alga cultivada a escala comercial en Latinoamérica y que representa el 25% de producción de este tipo nivel país. Acá la entrevista completa al doctor Murúa. --- Send in a voice message: https://anchor.fm/entrevistas-radio-sago/message

Biobanks, which are repositories of human biological materials, will shape the future of life science research. This means India needs laws to govern biobanks, that address issues like ethics, data protection, and consent. In this episode, Shambhavi Naik and Priyal D'almeida discuss the importance of biobanking, the regulations currently in place, and what India's biobanking laws should look like.Check out our issue brief on the subject: Issue Brief: Biobanking Policies in India.Click here to know more about our course on “Ethical Reasoning in Public Policy” Follow Shambhavi on Twitter: https://twitter.com/thenaikmicFollow Priyal on Twitter: https://twitter.com/LynciaPriyalIndia's Global Outlook SurveyAs India plays an increasing role in shaping the course of world events, the future of India's foreign policy will be marked by tricky trade-offs and tough choices. What are the approaches that you think India should prioritise? Click here to take the survey and let us know your views on India's foreign policy.You can listen to this show and other awesome shows on the new and improved IVM Podcast App on Android: https://ivm.today/android or iOS: https://ivm.today/iosYou can check out our website at http://www.ivmpodcasts.com

Today my guest is Alexandra Giardina, Pathologists' Assistant student and Biorepository Consultant. What we discuss with Alexandra: Her research experience in neurosignaling physiology Cancer research and how this introduced her to pathology and biobanking How she discovered the pathologists' assistant field while working in biobanking Her work with Audobon Bioscience Her thoughts on the role of a pathologists' assistant in biobanking Her experience as a pathologists' assistant student How the pandemic affected her program and how the program adapted Why she thinks it is important to diversify your skillset Links for this episode: Health Podcast Network  LabVine Learning The ConfLab from LabVine Dress A Med scrubs   Tulane University Pathologists' Assistant Program Audobon Bioscience Episode 6: Sarah Garner - Garner's Guide to Gross Anatomy Episode 17: Heidi Wagner - Biobanking and Medical Ethics   People of Pathology Podcast: Website Twitter

Direct-to-consumer genetic testing has been in the news this week with the recent IPO of 23andMe. Thus, we are revisiting our forum from September 2017 on biobanking, genetics, and the competing interests of individuals, businesses, and society in the collection and use of genetic samples. ------- Are we now approaching a time when we could all live, at least in freezers, forever? Modern collection and storage of biological samples make possible a kind of "immortality" for anyone who has ever had a saliva sample frozen for genealogical testing or a blood sample stored in medical collections. New technologies, like CRISPR for gene editing, expand possible future uses of biological materials stored around the world. The story of Henrietta Lacks, popularized in a book by Rebecca Skloot and an HBO special starring Oprah Winfrey, illustrates the ways that a single person's cells and tissues can take on lives of their own as research material. In 1953, just before her death, Lacks's cancer cells yielded the oldest and most common human cell line still used in research. There has been significant public interest in her remarkable story, but the "immortality" of people like Henrietta Lacks raises pressing questions for all of us. Who owns and controls bodily materials extracted from research subjects and patients? Who can profit from the cells and genes that make us who we are? How do we weigh the value of personal privacy and an individual's sense of self against the potential for medical progress? How do imbalances of wealth and power influence questions of consent, exploitation, and identity for people who provide biological materials? These questions framed a public forum organized by the Consortium and hosted by the American Philosophical Society on September 28, 2017. Find this presentation and further resources on the Consortium's website at: www.chstm.org/video/51

Today's episode will focus on the topic of using genomics to accelerate drug development.  Our host is Tõnu Esko, BC Platforms SAB Chairman and Vice Director of the Institute of Genomics University of Tartu, where he also holds a Professor of Human Genomics position. He is head of the Estonian Biobank Innovation Center and focuses on public private partnerships and innovation transfer. Dr. Esko is also a research scientist at the Broad Institute of Harvard at MIT. He acts as one of the senior leaders for Estonian personalized medicine programs and serves as a scientific advisor for several companies.  Our guest today is Iris Grossman, on the leading edge of Personalized Medicine, Big Data Analytics and Biotech R&D for 20 years. She is Acting CSO of Amide and advises other biotech in her field of expertise. She has held leadership positions and or consulted for top big pharma GSK, Eli Lilly, Takeda and Teva, where she was VP Head of early stage development, startup and consultancies. She specializes in leveraging high dimensional genomic insights and E-health as engines of therapeutic discovery, development and Lifecycle Management across a wide range of modalities and therapeutic areas. Iris also serves as SAB member of BC platforms, Tipa Biobank, Eleven Therapeutics and CGRP Diagnostics. She earned her B.Sc. in Medicine at the Technion, and a PhD in Medicine, Population Genomics and Pharmacogenomics for the Technion, co-mentored with the Weitzman Institute. Next, she was a postdoc fellow in Personalized Medicine and Population Genomics at Duke University. What is covered: - The benefits of using big data in drug discovery - Specific examples of how the genetics could be helpful in the drug discovery, such as the contribution of human genetics and genomics to fighting COVID - The recommendations to stakeholders for collaborating within the industry for the sake of innovation  - How biobanks can potentially act as middlemen for this new type of collaboration Resources: - The Institute of Genomics, University of Tartu https://genomics.ut.ee/en - The Estonian Biobank https://genomics.ut.ee/en  - Amide Technologies https://www.amidetech.com/ - GSK https://www.gsk.com/ - Eli Lilly https://www.lilly.com/ - Takeda https://www.takeda.com/ - Teva Pharmaceutical https://www.tevapharm.com/ - Tipa Biobank https://www.ksminnovation.com/biobank - Eleven Therapeutics https://eleventx.com/ - CGRP Diagnostics http://cgrpdiagnostics.com/ Connect with Iris Grossman: - https://www.linkedin.com/in/irisgrossman/ Connect with Dr. Tõnu Esko:  - https://www.linkedin.com/in/tõnu-esko-24511524/  Connect with BC Platforms:  - https://www.bcplatforms.com  - https://www.linkedin.com/company/bc-platforms/  - sales@bcplatforms.com 

Taking a look at how long we spend sitting, and what to do about it; assessing the cumulative affect of yearly weight gain; the oral microbiome and our ancestors; aiming for a brain biobank; and Q&A

Today's podcast will focus on the topic of accelerated insights from data for preventative health innovation. The podcast sheds light on industry challenges and expectations as well as innovative approaches to collaboration.  This discussion is led by Tõnu Esko, BC Platforms SAB Chairman and Vice Director of the Institute of Genomics University of Tartu, where he also holds a Professor of Human Genomics position. He is head of the Estonian Biobank Innovation Center and focuses on public private partnerships and innovation transfer. Dr. Esko is also a research scientist at the Broad Institute of Harvard at MIT. He acts as one of the senior leaders for Estonian personalized medicine programs and serves as a scientific advisor for several companies.  Our speaker today is Michael Geer, the co-founder of Humanity along with Peter Ward. Humanity is a health tech startup that enables you to find your rate of aging, and do what you can do to slow your aging down. Michael Geer is a serial tech entrepreneur, having amassed over a billion users with Badoo, AnchorFree, and even more revenue over his years building meaningful consumer focused technology. He wakes up every day working on how to best enable people with superpowers.  What is Covered: - What are the main obstacles to innovation in healthcare - How to open the access to different data types, and leverage this knowledge in order to build a complex health guide - The importance of democratization of data, federated access, and differential privacy in making data readily usable by other people - What scientific insights Humanity uses to build their products - How Humanity manages the complexity of its data model, and the feedback it provides to their customers Resources: - The Institute of Genomics, University of Tartu https://genomics.ut.ee/en - The Estonian Biobank https://genomics.ut.ee/en  - Humanity https://www.humanity.health/ - OpenMind https://openmindplatform.org/ - BioAge Labs https://bioagelabs.com/ Connect with Michael Geer: - https://www.linkedin.com/in/michaelgeer Connect with Dr. Tõnu Esko:  - https://www.linkedin.com/in/tõnu-esko-24511524/  Connect with BC Platforms:  - https://www.bcplatforms.com  - https://www.linkedin.com/company/bc-platforms/  - sales@bcplatforms.com 

While there is a diversity of laboratory information systems available, there is no one system used by bio-banks. Furthermore, there is an increased utilization of digital whole-slide scanning technology in converting slides made from biobanking into digital whole slide images. In this CAPcast, Duke Medical Center pathology resident Dr. Richard Davis interviews leading pathology informatics expert Dr. Raj Dash about biobanking and its integration with various LIS technologies. Dr. Dash is also at Duke Medical Center. For more information about biobanking, please visit the Biorepository Accreditation Program section on CAP.org: https://capatholo.gy/3rzSPkg.

Today's podcast will focus on the topic of the journey to a safe and secure global data access. This podcast sheds light on industry challenges and expectations, as well as innovative approaches to collaboration. The discussion is led by Tõnu Esko, BC Platforms Scientific Advisory Board Chairman, and Vice Director of the Institute of Genomics at the University of Tartu, where he also holds a Professor of Human Genomics position. He is the Head of Estonian Biobank Innovation Center, and focuses on public-private partnerships and innovation transfer. Dr. Esko is also a research scientist at the Broad Institute of Harvard and MIT. He acts as one of the senior leaders for Estonian Personal Medicine Program, and serves as scientific advisor for several companies.  Our speakers today are Jennifer Cubino and Anni-Ahonen Bishop from BC Platforms.  Jennifer Cubino is a BC Platforms COO, Customer Success and Data Science. She has many years of experience as a clinical research industry executive, most recently at IQVIA/Quintiles. She has a diverse background, including creating and leading strategic partnerships, clinical trial operations, business strategy, precision medicine, technology development and oncology. Her focus is developing high performing and engaged teams capable of tackling rapidly changing markets. With seven years of experience as a former IRB member at Tufts Medical Center, Jennifer has a deep commitment to patient wellbeing.  Anni-Ahonen Bishop has held several positions at BC Platforms before being appointed as Pharma and Research Solutions Director. She first worked as a science expert and leader as a project manager and team leader. Miss Anni Bishop has extensive experience in science communications, software design, product development and management of both large customer projects and international cross disciplinary collaboration projects.  What is covered: - The main challenges for pharma industry in accessing healthcare data  - The harmonization of different data silos as a way of approaching and managing the technical challenges  - How BC Platforms can provide help to different data custodians to interact with the industry and make the data more readily available - How pharma and biobanks can collaborate in order to preserve data privacy and keep it under the legal and ethical framework Resources: - The Institute of Genomics, University of Tartu https://genomics.ut.ee/en - The Estonian Biobank https://genomics.ut.ee/en  - OMOP Common Data Model https://www.ohdsi.org/data-standardization/the-common-data-model/ - General Data Protection Regulation https://gdpr-info.eu/ - The Health Insurance Portability and Accountability Act https://www.hhs.gov/hipaa/index.html Connect with Jennifer Cubino: - https://www.linkedin.com/in/jennifercubino/ Connect with Anni Ahonen-Bishop: - https://www.linkedin.com/in/anniahonenbishopp/  Connect with Dr. Tõnu Esko:  - https://www.linkedin.com/in/tõnu-esko-24511524/  Connect with BC Platforms:  - https://www.bcplatforms.com  - https://www.linkedin.com/company/bc-platforms/  - sales@bcplatforms.com   

Today's episode will focus on the topic of real world data access for label expansion. We are holding an open discussion with a few key leaders on how real world data can be applied in drug development to enhance research and accelerate discoveries. This podcast sheds light on industry challenges and expectations, as well as innovative approaches to collaboration.  The discussion is led by Tõnu Esko, BC Platforms Scientific Advisory Board Chairman, and Vice Director of the Institute of Genomics at the University of Tartu, where he also holds a Professor of Human Genomics position. He is the Head of Estonian Biobank Innovation Center, and focuses on public-private partnerships and innovation transfer. Dr. Esko is also a research scientist at the Broad Institute of Harvard and MIT. He acts as one of the senior leaders for Estonian Personal Medicine Program and serves as scientific advisor for several companies.  Our speaker today is Jacek Nowak, Amgen's Executive Medical Director for European Midsize Markets. Jacek has been active as a pharmaceutical industry leader for over 25 years. Prior to joining Amgen in 2003, Jacek served as Medical Director for Central Europe at Wyeth, and he also worked as a Medical Doctor at the Cardiology and Intensive Care Unit at the University Hospital of Slaskie School of Medicine in Katowice, Poland. Jacek holds a degree of Medical Doctor and earned his doctorate on research work on leptin receptor polymorphism. Jacek holds a Diploma in Pharmaceutical Medicine from the Royal College of Physicians in London. His expertise pertains to the area of organ transplantation, oncology, cardiology and metabolic disorders.  What Is Covered:  - What Real World Data is and how it's connected with drug development - The opportunity of supplementing randomised clinical trial analysis with the application of real world data - The complexity of working with different countries, healthcare systems, and different ways in which the data is collected, in order to use the real world data in decision making process - Expectations towards the real world data and the key properties that big data banks and healthcare systems should keep in mind when partnering with the industry in this space - Wearables in medicine, telemedicine, digitalization of data, and other personalised medicine trends for the future of healthcare and data research Resources:  - Amgen https://www.amgen.com/  - The Estonian Biobank https://genomics.ut.ee/en  Connect with Jacek Nowak: - https://www.linkedin.com/in/jacek-nowak-121684/  Connect with Dr. Tõnu Esko:  - https://www.linkedin.com/in/tõnu-esko-24511524/  Connect with BC Platforms:  - https://www.bcplatforms.com  - https://www.linkedin.com/company/bc-platforms/  - sales@bcplatforms.com 

Welcome to the BC Platforms Podcast!  BC Platforms is the global leader in providing a powerful data discovery and analytics platform, as well as data science solutions for personalized health care. BC Platforms enables cross-functional collaboration with our global federated network of data partners. This episode is an open discussion with three key leaders in the healthcare data industry.   Tõnu Esko is the Professor of Human Genomics at the University of Tartu, and the longtime leader and member of the Senior Management Board for the Estonian Biobank.  Sirpa Soini is the Director of The Finnish Institute for Health and Welfare Biobank (THL Biobank). She has been collaborating with BBMRI-ERIC, and BBMRI-ERIC.fi in Finland, and with a background as a lawyer, she has also been involved in legal and ethical compliance work.  Outi Törnwall is Data Partnership Director at BC Platforms, driving forward and building a data partnership network that enables sharing of data and collaboration, particularly in industry driven research. What is Covered:  - Overview of the work of Estonian Biobank, THL Biobank and Data Partnership at BC Platforms - The increase of real-world data and the challenges of creating meaningful databases across different industries and countries - What positive results have been achieved so far within global data partnerships and networks  - How to bridge the gaps between academic research, industry needs and policy makers  - Advice for researchers and industry stakeholders for a more effective collaboration that benefits patients and the society as a whole Links and Resources Mentioned in This Episode:  - BC|RQUEST - Global Data Partner Network https://bcrquest.com/  - Estonian Biobank https://genomics.ut.ee/en  - THL Biobank https://thl.fi/en/web/thlfi-en   - Fingen Research Project https://www.finngen.fi/en  - Europe Biobank Week https://europebiobankweek.eu/  Connect with Sirpa Soini: -  https://www.linkedin.com/in/sirpasoini/  Connect with Outi Törnwall:  -  https://www.linkedin.com/in/outitornwall/  Connect with Dr. Tõnu Esko:  - https://www.linkedin.com/in/tõnu-esko-24511524/  Connect with BC Platforms:  - https://www.bcplatforms.com  - https://www.linkedin.com/company/bc-platforms/  - sales@bcplatforms.com  

Welcome to the first episode of the BC Platforms podcast! BC Platforms is the global leader in providing a powerful data discovery and analytics platform, as well as data science solutions for personalized health care. BC Platforms enables cross-functional collaboration with our global federated network of data partners. In today's episode we are discussing shaping a data access framework for population health. We will shed light on industry challenges and expectations, as well as innovative approaches to collaboration. This episode is hosted by Tõnu Esko, BC Patforms SAB Chairman and Vice Director at the Institute of Genomics at the University of Tartu. He also holds a Professor of Human Genomics Position, and is the Head of the Estonian Biobank Innovation Center focusing on public-private partnerships and innovation transfer. Dr. Esko is a research scientist at the Broad Institute of Harvard and MIT. He acts as one of the senior leaders of the Estonian Personalized Medicine Program, and served as a scientific advisor for several companies.  Our guest today is Gerry Reilly, Chief Technology Officer at Health Data Research UK. Having joined HDR UK in 2018, Gerry is now a Technologist in Residence focusing on the development of HDR UK's international work and long term technology strategy. Gerry is a fellow of the British Computer Society, Chartered Engineer and Chartered IT professional. He's an academic assessor for the British Computer Society, and a member of the industrial advisory board for the School of Electronic, Engineering and Computer Science at QMUL. What Is Covered:  - The burning problems and the obstacles for data sharing in the global health data research community - The three key areas HDR UK focuses on and the role of HDR UK Innovation Gateway - How the health data research ecosystem currently works in the UK - The cultural shifts needed in order to harmonise data access management across the health sector - How the COVID pandemic has accelerated the work on data access and data quality harmonisation - The steps towards a broad international collaboration in health data research   Links and Resources Mentioned in This Episode:  - Health Data Research UK https://www.hdruk.ac.uk/  - Health Data Research Innovation Gateway https://www.healthdatagateway.org/  - UK Health Data Research Alliance https://ukhealthdata.org/  - UK Biobank https://www.ukbiobank.ac.uk/  - Genomics England https://www.genomicsengland.co.uk/  - Dublin Core Metadata Initiative https://dublincore.org/  - International COVID-19 Data Alliance https://icoda-research.org/  - The Estonian Biobank https://genomics.ut.ee/en  Connect with Gerry Reilly: - https://www.linkedin.com/in/gerry-reilly-7290681/  Connect with Dr. Tõnu Esko:  - https://www.linkedin.com/in/tõnu-esko-24511524/  Connect with BC Platforms:  - https://www.bcplatforms.com  - https://www.linkedin.com/company/bc-platforms/  - sales@bcplatforms.com  

One new start-up microbiology company, Brick Built, is focused on the potential of the human oral microbiome. Our two microbiome product managers at DNA Genotek, Dr. Heloise Breton, and Laura Cunningham, had the pleasure of speaking with Brick Built Therapeutics co-founder Dr. Brian Klein about the role and future potentials of the oral microbiome in our health and biotech industry.

Jacob Teixeira is a project manager for a BioBanking and Biosolutions company based in Massachusetts. In this episode, Jacob shares his experiences in track during his high school and college career. Also, he talks about struggling with his sexuality and coming out to friends and family. In addition, we talked a lot about mental health and being vulnerable. Jacob talks about the loss of his father and how that's impacted his relationship with his family. Join us in this amazing discussion on sexuality, family, and mental health.

Pathologists have long been at the forefront of biobanking practices, assuring that biospecimens from patients are properly collected and processed for diagnostic procedures. During the ongoing COVID-19 pandemic, pathologists and laboratory technicians have had to develop and implement new biosafety procedures to protect themselves and patients and they are also often involved in research into new therapies, explains Dr. Jim Vaught, editor-in-chief of the journal Biopreservation and Biobanking. In this CAPcast, Dr. Vaught discusses the special challenges involved in developing protocols to work with biospecimens collected from patients during an infectious disease emergency, as well as the role that biobanks play in the development of COVID vaccines and therapies. More resources related to biobanking and biorepositories can be found on CAP.org under the Biorepository Accreditation Program: https://capatholo.gy/3rzSPkg.

From our symposium - Scaling Omics Approaches to Population Size: the unedited talk of Kristian Hveem, Norwegian University of Science and Technology.On the topic: Biobanking and precision medicine

"Null results are still results" - Rachel Kelly About Rachel Kelly Rachel Kelly is a TRSM MBA candidate and Research Manager at the Centre for Addiction and Mental Health. Leveraging experience and certifications as a project manager (PMP) and clinical research professional (ACRP-CP), Rachel has supported large-scale projects within the cancer, biobanking and mental health research environments. Rachel is passionate about supporting research that engages participants and their families, and translates innovations from (lab) bench to bedside. Connect With Rachel LinkedIn: https://www.linkedin.com/in/rachel-kelly-sferrazza-pmp-7a3aa6a2/ Charity of The Month Y&D donates all of its revenue to charity. This month's featured charity is Cancer Care Manitoba. You can make your donation here: https://www.cancercare.mb.ca/Ways-To-Help/donate. Send us your donation receipt to be mentioned next episode. Connect With The Yonge and Dundas Team Y&D takes questions and feedback from our listeners. You can contact Roshan via: Email: roshansahu@protonmail.com Twitter/Instagram: @roshandsahu LinkedIn: https://www.linkedin.com/in/roshandsahu/ Copyright Roshan Dev Sahu 2020. All Rights Reserved. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

Principal Investigator for the Bay Area Lyme Disease Biobank, Liz Horn, PhD, MBI, discusses the Lyme Disease Biobank which has enrolled over 900 participants, supporting over 50 research projects so far. They support research projects across the nation by providing coveted serum, whole blood, urine and tissue samples to scientific researchers.

Today my guest is Heidi Wagner.  She is a pathologists' assistant and the head of operations of a biobank.What we discuss with Heidi Wagner:Her career path and how it led her to biobankingHow tissue is procured by a biobankHeidi's experience at the ESBB conferenceISBER and the planned joint conference with UHNHer presentation on Ethics in biobankingLinks for this episode:European, Middle Eastern, and African Society for Biopreservation and Biobanking websiteInternational Society for Biological and Environmental Repositories websiteISBER/ASCP Biobanking Qualification information herePeople of Pathology Podcast:WebsiteTwitter 

Most biorepositories have not traditionally paid attention to the financial aspects of their operations, which has led to problems in the long-term sustainability of some academic, government and commercial biobanking operations, explains Dr. Jim Vaught, editor-in-chief of the journal Biopreservation and Biobanking, in this CAPcast. Dr. Vaught has studied the challenges involved in the economics and sustainability over the past 10 years and has published several papers on these topics. In this CAPcast, Dr. Vaught will discuss why all biorepository directors need to understand the costs of setting up and operating their facilities and how to develop a business strategy. For more resources related to biobanking and biorepositories, including the CAP’s Biorepository Accreditation Program, please visit CAP.org and search for biorepository.

The unedited talk of Kristian Hveem, Head of Biobank Norway, and PI of Hunt Biobank, at the symposium "Future of Biobanking"

The unedited talk of Mark Divers, Head of Karolinska Institute Biobank in Stockholm, at the symposium "Future of Biobanking"

In this year’s last episode we take a look in the mirror. Having so far focused on the great work of our collaborators, we now turn the attention on biobanking itself. Inspired by our recent co-hosted PhD course and symposium: “The Future of Biobanking”, and with the help of biobanking expert Eva Ortega-Paino, we explore the past, present and future of biobanking. The Danish National Biobank is a treasury of science for international health research. It contains 10 million biosamples across an array of diagnostic categories, as well as the Danish Biobank Register that links over 25 million biosamples in Danish biobanks to vast amounts of register information. This podcast will give an insight into some of the amazing research done through the Danish National Biobank, and hopefully inspire researchers to utilize this potential in the future.

In recent years, biobanking has become increasingly vital to furthering the promise of precision medicine. However, academic, government and commercial biobanking operations have also come under increased pressure to balance their budgets and plan for long-term sustainability in the face of budget shortfalls and increased competition for limited research funding. As one of the primary medical specialties engaged in biobanking, pathologists face these challenges in their institutions, explains Dr. Jim Vaught, editor-in-chief of the journal Biopreservation and Biobanking (https://capatholo.gy/2nOY6Yx), in this CAPcast. Dr. Vaught has studied the challenges involved in the economics and sustainability over the past 10 years and has published several papers on these topics. Learn more about the CAP's Biorepository Program: https://capatholo.gy/2LveVSV.

Dr. K. Stephen Suh, a Precision Medicine Expert, based in the United States, participates in Risk Roundup to discuss BioBanking Trends. Biobanking Trends Technology has now made it possible for broad sharing of information, rapid analysis, and automation of testing.  Moreover, the whole genome data and digital sharing capability are improving the research capabilities. From […] The post Biobanking Trends appeared first on Risk Group.

Disparities exist in enrollment in clinical trials and biorepositories among adults with low socioeconomic status, racial and ethnic minority groups and individuals who live in rural areas. Diverse participation is necessary to identify the most effective treatments in different groups. The purpose of this study was to use qualitative methods to identify factors that may affect the likelihood that members of underrepresented groups choose to participate in clinical trials and/or biobanking. We conducted 14 focus groups and seven telephone interviews in urban and rural areas of Louisiana to: (1) identify barriers and facilitators to participation; and (2) elicit input in crafting clear, culturally appropriate language and recruitment strategies. Of 103 participants, 25 were safety-net healthcare providers, 18 were primary care or oncology clinic patients, and 60 were members of social and faith-based groups. Patients and community participants were English-speaking, 79% were African American, 81% were female and 24% lived in rural areas. Barriers to participation identified were lack of knowledge about clinical trials and biobanks; limited specific information and access to participation, trust and privacy concerns about clinical trials and biobanking Facilitators included: altruism, high interest in medical research particularly studies that might benefit them or their families; plain language, culturally appropriate information; convenient access to studies; and input of a trusted provider. In addition, all primary care providers were interested in having clinical trial options available for their patients but did not have time to search for available trials. Results of this study can inform the development of education materials and strategies to increase participation of underrepresented groups in clinical trial and biobanking. Davis TC, Arnold CL, Mills G, Miele L. A Qualitative Study Exploring Barriers and Facilitators of Enrolling Underrepresented Populations in Clinical Trials and Biobanking. Front Cell Dev Biol. 2019;7:74. Published 2019 Apr 30. doi:10.3389/fcell.2019.00074. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Sections of the Abstract, and Conclusion and Recommencations are presented in the Podcast. Access the full-text article here: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6502895/

Are we now approaching a time when we could all live, at least in freezers, forever? Modern collection and storage of biological samples make possible a kind of "immortality" for anyone who has ever had a saliva sample frozen for genealogical testing or a blood sample stored in medical collections. New technologies, like CRISPR for gene editing, expand possible future uses of biological materials stored around the world. The story of Henrietta Lacks, popularized in a book by Rebecca Skloot and an HBO special starring Oprah Winfrey, illustrates the ways that a single person's cells and tissues can take on lives of their own as research material. In 1953, just before her death, Lacks's cancer cells yielded the oldest and most common human cell line still used in research. There has been significant public interest in her remarkable story, but the "immortality" of people like Henrietta Lacks raises pressing questions for all of us. Who owns and controls bodily materials extracted from research subjects and patients? Who can profit from the cells and genes that make us who we are? How do we weigh the value of personal privacy and an individual’s sense of self against the potential for medical progress? How do imbalances of wealth and power influence questions of consent, exploitation, and identity for people who provide biological materials? These questions framed a public forum organized by the Consortium and hosted by the American Philosophical Society on September 28, 2017.

Commentary by Dr. Valentin Fuster

Two leaders from the Coriell Institute for Medical Research join the show to discuss biobanking. Nahid Turan, Chief Laboratory Officer, and Alissa Resch, Chief Scientific Officer, lead separate aspects of the Institute scientific efforts.Coriell is known for its impact in the world of biobanking. If you’ve ordered biological materials in the past for research, there’s a good chance you’ve ordered from them before. In its 65 year history, Coriell has partnered with many federal, private and nonprofit organizations, offering expertise in the collection, processing, storage and distribution of biological materials, and in the process built one of the most diverse and important collections of biomaterials in the world. It’s because of their collection that endeavors like the Human Genome Project were possible and that the science of personalized medicine thrives today.On This Episode We Discuss:Definition of Biobanking and ProcessSample Tissue and Species TypesNumber of SamplesDisease RepresentationApproach to Finding Specific SamplesResearch Access and ShipmentOrganizations, Institutions and Projects SuppliedIncluding the Human Genome Project and the 1,000 Genomes Project!Managing Big Bio DataTo learn more about Coriell head over to their website, specifically their biobanking page. Stay updated with their latest news by following them on Twitter.Stay tuned for the next new episode on April 5th, 2019. This will be the 100th episode of DNA Today! To celebrate I interview Carl Zimmer, a popular science writer for the New York Times and has also contributed to The Atlantic, National Geographic, Time and Scientific America. He has won the Stephen Jay Gould Prize Among many other honors for his journalism. Zimmer teaches science writing at Yale University. His books include Parasite Rex, Evolution: The Triumph of an Idea, Microcosm and his latest, She Has Her Mother’s Laugh which we will be discussing on next month’s episode. So tune back in on April 5th to hear the interview!New episodes are released on the first Friday of the month. See what else I am up to on Twitter, Instagram, Facebook and iTunes. Any questions/inquiries are welcome and can be sent to info@DNApodcast.com.

For the next episode in our summer series on human tissue sample quality and biobanking, we turn to a veteran biobanker in the U.K. who managed several projects there including the U.K. Parkisons’ Disease Society Brain Bank at Imperial College. Today we talk to Kirstin Goldring, Principal Scientist at Astra Zeneca where she’s in charge of Human Biological Sample Strategy and Governance. Kirstin is a counselor at the European Society for Biopreservation and Biobanking and also a member of ISBER or the International Society for Biorepositories.

Proper handling during the collection and processing of specimens is crucial for producing reliable results.  These pre-analytical steps are highly vulnerable to the introduction of experimental bias and variance, which may drastically degrade specimen quality.  Analytes are affected differently by uncontrolled variations in specimen collection, processing, and storage protocols. The August 2018 issue of Clinical Chemistry includes a Review article from the Precision Medicine and Pharmacometabolomics Task Group of the Metabolomics Society.  The authors summarize the current variability among pre-analytical processing and biobanking procedures for metabolomics research and provide recommendations for best practices.

When former President Obama’s team released the paperwork for what’s become the All of Us Research Program, in the part about biobanking, the wording specified that the biobanks applying for the grants be “CLIA compliant.”

In this latest edition of NCTalks, Sharon Salt (Editor) speaks with Jens Kuhle, a neurologist at the University Hospital Basel, Switzerland. Jens is the head of the multiple sclerosis (MS) center at the hospital and runs a research group called ‘Translational Biomarkers and Biobanking’. In this podcast, Jens speaks about monitoring MS using blood neurofilament light protein and how this could impact the way we monitor and treat MS. Jens also discusses how he overcame the hurdle of measuring neurofilament in the blood and what the next steps are for his team.

Kerry R. Wiles of Vanderbilt University speaks to Cambridge Healthtech Institute on July 11, 2017. Her institution will be co-hosting and she herself will be a presenter and short course instructor during the Leaders in Biobanking Congress, October 25-27 in Nashville, Tennessee. Topics Include: Building the Cooperative Human Tissue Network with Lean Six Sigma principles to improve processes, how shifts in clinical care and surgical care affect biorepositories and scientists, and what it takes to sustain a biobank. For more information, please visit http://BiobankingCongress.com/Agenda#Day3 and http://BiobankingCongress.com/Short-Courses

Sarah Gray of the American Association of Tissue Banks speaks to Cambridge Healthtech Institute on July 7, 2017. She will be a presenter and short course instructor during the Leaders in Biobanking Congress, October 25-27 in Nashville, Tennessee. Topics Include: Expectations about the process of donating post-mortem tissue for biospecimen research, possible process improvements to better serve patients, and connecting researchers with donor families to build biobank credibility and enable public support of biospecimen donation for biomedical research. For more information, please visit http://www.BiobankingCongress.com/Agenda/ and http://www.BiobankingCongress.com/Short-Courses/

Biobanking for Pulmonary, Critical Care and Sleep Research

Andrew Brooks of BioProcessing Solutions Alliance and Rutgers University speaks to Cambridge Healthtech Institute on August 3, 2016. Dr. Brooks will be presenting at the Leaders in Biobanking Congress, September 7-9 in Baltimore, Maryland. Topics include the evolution of biobanking quality control and standardization resources, goals and activities at Rutgers, challenges in biospecimen collection and storage for genomic research and clinical application, and harmonized biobanking to support precision medicine initiatives across multiple applications.

Anton Wellstein of Georgetown University Medical School speaks to Cambridge Healthtech Institute on August 1, 2016. He will be a presenter at the Leaders in Biobanking Congress, September 7-9 in Baltimore, MD. Topics include the importance of pre-analytical processing of samples, circulating nucleic acids in cancer treatment monitoring, and persistent challenges when linking cancer molecular markers with clinical information.

Susan Airhart of The Jackson Laboratory and Dr. Jens Rueter of Eastern Maine Medical Center speak to Cambridge Healthtech Institute on July 28, 2016. They will co-present a case study of their biobanker/R&D partnership at the Leaders in Biobanking Congress, September 7-9 in Baltimore, MD. Topics include the genesis and resources of The Jackson Laboratory’s PDX Consortium and the EMMC BioBank, their collaboration’s advancement of translational research, and how research with PDX models and biobank partnerships might evolve to contribute further to preclinical drug development and patient care. For more information, please visit http://www.HealthTech.com/Biobanking/Agenda#Day3

Ab Oktober 2016 startet an der MedUni Graz der erste englischsprachige Fernlehrkurs in Biobanking europaweit deren Ausbildung den gesamten Arbeitsablauf in einer Biobank umfasst. Studierende schließen nach 4 Semestern mit dem „Master of Science in Biobanking“ ab, womit ihnen auch international die Türen offen stehen. Direktor der Biobank Graz, Dr. Berthold Huppertz, gibt Einblicke über Ausbildung, Arbeitsalltag und Karrieremöglichkeiten Autor:

This week on the graphic medicine podcast, Leah Eisenberg talks about her work as a lawyer and bioethicist using comics to help make biobank more comprehensible and consent to bio banking more meaningful. In the “What Are You Reading?!” segment, Leah updates us on her comics & medicine work and recommends a few books she’s enjoyed recently. Download Episode

Michael Roehrl of the UHN Program in BioSpecimen Sciences and Anthony Joshua of Princess Margaret Cancer Centre speak to CHI on June 2, 2015. Drs. Roehrl and Joshua will be co-presenting a Case Study of their biobanker/biouser partnership at the Leaders in Biobanking Congress, July 14-16 in Toronto, Canada. Topics include the Rapid Autopsy Program of Princess Margaret Cancer Centre, the mutual influence of lab research and clinical practice work, biospecimen management and collection of robust data, patient contributions to cancer research and understanding cancer therapy resistance. For more information visit http://www.Healthtech.com/Biobanking

Suzanne Vercauteren of BC Children’s Hospital and University of British Columbia speaks to CHI on May 20, 2015. Dr. Vercauteren will be a presenter at the Leaders in Biobanking Congress, July 14-16 in Toronto, Canada. Topics include biospecimen collection and storage of clinical data at the BCCH BioBank, practices for ensuring biobank sustainability, ethical and operational considerations of planning an institutional biobank for children and women, and the importance of public engagement. For more information, visit http://www.Healthtech.com/Biobanking

Biobanking for clinical or research purposes includes the collection, processing, storage and analysis of biological specimens. It is now well-recognized that biobanking involves a complex array of technical, ethical, and regulatory considerations.

An-Dinh Nguyen interviews Carolyn Compton of National Biomarkers Developmental Alliance, Complex Adaptive Systems Institute, Mayo Medical School and Arizona State University on July 23, 2014. Dr. Compton will be a plenary keynote speaker at the Leaders in Biobanking Congress and Cancer Diagnosis at the Crossroads: Precision Medicine Driving Change event, September 15-17 in Seattle, WA. Topics include effects of pre-analytical variables on human biospecimens during acquisition and processing, the importance of fit-for-purpose samples and how biobanks play a role in making personalized cancer therapies possible.

An-Dinh Nguyen interviews James M. Olson of Fred Hutchinson Cancer Research Center, Seattle Children’s Hospital, Presage Biosciences and Blaze Bioscience on July 18, 2014. Dr. Olson will be a plenary keynote speaker at the Leaders in Biobanking Congress and Cancer Diagnosis at the Crossroads: Precision Medicine Driving Change event, September 15-17 in Seattle, WA. Topics include the scorpion venom-derived molecular imaging agent Tumor Paint and its potential applications for cancer treatment, optide therapeutics, drug research and development breakthroughs in pediatric brain tumors through PDX models and more.

An-Dinh Nguyen interviews Stephen Schmechel of NWBioTrust and University of Washington on July 17, 2014. Dr. Schmechel will be a short course instructor for Biobanking Is More than Sample Storage and Management and speaker at the Leaders in Biobanking Congress and Cancer Diagnosis at the Crossroads: Precision Medicine Driving Change event, September 15-17 in Seattle, WA. Topics include critical business considerations for running biobanks to advance personalized medicine, support of translational research and clinical trials through a biobanker/biouser partnership and collaborations between University of Washington, Fred Hutchinson Cancer Research Center, Seattle Children's Hospital and elsewhere.

Guest: Liz Horn, PhD, Patient Advocate Bio and Contact Info Listen (8:22) What is biobanking? Listen (4:05) Sample collection and the diagnostic odyssey

Aaro TUPASELA, University of Helsinki

Aaro TUPASELA, University of Helsinki

An-Dinh Nguyen interviews Sherilyn Sawyer of BWH/Harvard Cohorts Biorepository, Brigham and Women’s Hospital on September 10, 2013. Dr. Sawyer will be speaking during the Biospecimens and Translational Science session at the Leaders in Biobanking Congress, November 4-5, in Indianapolis, IN. Topics include the evolution of biospecimen collection and usage, biouser needs, future challenges and opportunities.

An-Dinh Nguyen interviews Brian Chadwick of LookLeft Group LLC on September 10, 2013. Mr. Chadwick will be speaking during the Business of Running a Biobank session at the Leaders in Biobanking Congress, November 4-5, in Indianapolis, IN. Topics include regulatory compliance challenges of biospecimen management, software solutions, commercial vs. nonprofit biobanks, patient rights and more.

An-Dinh Nguyen interviews Allison Hubel of the Biopreservation Core Resource at the University of Minnesota on September 5, 2013. Dr. Hubel will be speaking during the Science of Supplying High-Quality Specimens session at the Leaders in Biobanking Congress, November 4-5, in Indianapolis, IN. Topics cover biobanking’s rising prominence, biospecimen collection and storage challenges, microfluidics applications for biopreservation and more.

Clinical Cancer Registries

Audio PodcastAired date: 3/27/2012 1:00:00 PM Eastern Time

Video Podcast (CC)Aired date: 3/27/2012 1:00:00 PM Eastern Time

Dr Sabine Kleinert Senior Executive Editor, The Lancet and Vice-Chair of the Committee on Publication Ethics (COPE), gives the fourth 2010 Research Integrity Seminar.

Dr Jane Kaye, Director of HeLEX-Centre for Health, Law and Emerging Technologies, University of Oxford, gives the third 2010 Research Integrity Seminar.